The Making of the COVID-19 Vaccines

The COVID-19 virus is studied and compared to researching a similar virus.

Once a viable candidate is created, the vaccines are first tested in a laboratory.

Small batches of the vaccine are created.

Small scale studies are performed.

Pharmaceutical companies determine when the vaccine is ready to move forward to clinical trials.

Scientists develop FDA guidelines for a quality control strategy.

Three phases of combined clinical trials
Trials must collect enough data to show the vaccine is safe and effective. The data submitted to the FDA is reviewed and analyzed by scientific experts.

1. Testing for safety, people begin to take part in trials. Trials wait enough time for volunteers to be exposed to COVID-19, which tells how effective the vaccine is.

2. Researching immune response and safety dosage, along with short-term side effects.

3. Assessing if the vaccine safely protects against COVID-19.

The COVID-19 vaccine was expedited because the whole world made it their number one priority and they crowdsourced their findings. Governments made it a priority to review and approve the vaccine.

Data is submitted on the vaccine's safety and efficiency to regulatory authorities for review and to gain approval.

Pharmaceutical companies continue to monitor all vaccines' effectiveness and safety.

Manufacturing and delivery - Require specialist facilities that are highly regulated by the Food and Drug Administration (FDA).

Results are taken to the U.S. Food and Drug Administration (FDA) for emergency use authorization, making the vaccine available for public health emergencies.

Once authorized by the FDA, production of the vaccine increases and is supplied to the public for usage.

VISIT: http://us.sodexo.com/getthefacts

SCAN FOR MORE INFORMATION

Source: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/vaccine-development-101